Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF

Journal of Molecular Histology

Volumn 44, Issue 4, 2013, Pages 433-445

  Wu, Yuan Yuan ^a   Chen, Li ^a   Wang, Gui Lan ^a   Zhang, Yi Xin ^b   Zhou, Jia Ming ^a   He, Song ^b   Qin, Jing ^a   Zhu, Yuan Yuan ^c  

^a NANTONG UNIVERSITY   (China)

^b NANTONG TUMOR HOSPITAL   (China)

^c Biomics (Nantong) Co Ltd   (China)

Author keywords

DGT siRNA; Hepatocellular carcinoma (HCC); NET 1; VEGF

Indexed keywords

ANGIOPOIETIN 2; CYCLIN D1; MESSENGER RNA; NET 1 PROTEIN; PROTEIN BCL 2; SMALL INTERFERING RNA; TETRASPANIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOPOIETIN-2; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN D1; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEP G2 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MICE; MICE, NUDE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880918759     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-012-9480-5     Document Type: Article

References (37)

1. Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66:6264-6270
2. Chen L, Wang Z, Zhan X, Li DC, Zhu YY, Zhu J (2007) Association of NET-1 gene expression with human hepatocellular carcinoma. Int J Surg Pathol 15:346-353 (Pubitemid 47476082)
3. Chen L, Li X, Wang GL, Wang Y, Zhu YY, Zhu J (2008) Clinicopathological significance of overexpression of TSPAN1, Ki67 and CD34 in gastric carcinoma. Tumori 94:531-538
4. Chen L, Zhu YY, Zhang XJ, Wang GL, Li XY, He S, Zhang JB, Zhu JW (2009) TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma. World J Gastroenterol 15:2270-2276
5. Chen L, Yuan D, Wang GL, Wang Y, Wu YY, Zhu J (2010a) Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma. J Korean Med Sci 25:1438-1442
6. Chen L, Yuan D, Zhao R, Li H, Zhu J (2010b) Suppression of TSPAN1 by RNA interference inhibits proliferation and invasion of colon cancer cells in vitro. Tumori 96:744-750
7. Chen L, Zhu Y, Li H, Wang GL, Wu YY, Lu YX, Qin J, Tuo J, Wang JL, Zhu J (2010c) Knockdown of TSPAN1 by RNA silencing and antisense technique inhibits proliferation and infiltration of human skin squamous carcinoma cells. Tumori 96:289-295
8. Cheng K, Mahato RI (2007) Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst 24:93-146 (Pubitemid 47324848)
9. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205-219 (Pubitemid 38167313)
10. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD (2001) Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 61:5389-5395 (Pubitemid 32694916)
11. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911 (Pubitemid 29407357)
12. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
13. Hashizume H, Falcon B, Kuroda T, Baluk P, Coxon A, Yu D, Bready J, Oliner J, McDonald D (2010) Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70:2213-2223
14. Hongo T, Kajikawa M, Ishida S, Ozawa S, Ohno Y, Sawada J, Ishikawa Y, Honda H (2006) Gene expression property of high-density three-dimensional tissue of HepG2 cells formed in radial-flow bioreactor. J Biosci Bioeng 101:243-250 (Pubitemid 44354394)
15. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W (1998) Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 8:529-532 (Pubitemid 28203073)
16. Lee SH, Mok H, Jo S, Hong CA, Park TG (2011) Dual gene targeted multimeric siRNA for combinatorial gene silencing. Biomaterials 32:2359-2368
17. Liu Y, Poon R, Li Q, Kok T, Lau C, Fan S (2005) Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65:3691-3699 (Pubitemid 40616346)
18. Maecker HT, Todd SC, Levy S (1997) The tetraspanin superfamily: molecular facilitators. FASEB J 11:428-442 (Pubitemid 27259984)
19. Mahato RI, Cheng K, Guntaka RV (2005) Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opin Drug Deliv 2:3-28 (Pubitemid 40123880)
20. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18:363-374 (Pubitemid 29041945)
21. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116:838-845 (Pubitemid 33108154)
22. Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y, Tsuneyoshi M (2006) CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 19:738-745
23. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y (1999) Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274:15732-15739 (Pubitemid 29254948)
24. Pang R, Poon RT (2006) Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242:151-167 (Pubitemid 44485315)
25. Qiu MB, Zhang JX, Liu LM, Gong BD, Wu BL, Zhu SS, Wen Y (2004) Inhibitory effects of antisense oligodeoxynucleotide on expression of vascular endothelia growth factor by human hepatocarcinoma cells. Hepatobiliary Pancreat Dis Int 3:552-557 (Pubitemid 39561966)
26. Raskopf E, Vogt A, Sauerbruch T, Schmitz V (2008) siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 49:977-984
27. Reed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17:2941-2953 (Pubitemid 29415256)
28. Scholz CJ, Kurzeder C, Koretz K, Windisch J, Kreienberg R, Sauer G, Deissler H (2009) Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas. Cancer Lett 275:198-203
29. Serru V, Dessen P, Boucheix C, Rubinstein E (2000) Sequence and expression of seven new tetraspans. Biochim Biophys Acta 1478:159-163 (Pubitemid 30136148)
30. Sherr CJ (1993) Mammalian G1 cyclins. Cell 73:1059-1065 (Pubitemid 23180481)
31. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Rafii S, Schwartz JD (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992-2998
32. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843-850
33. Wollscheid V, Kühne-Heid R, Stein I, Jansen L, Köllner S, Schneider A, Dürst M (2002) Identification of a new proliferation- associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas. Int J Cancer 99:771-775 (Pubitemid 34575692)
34. Yauch RL, Hemler ME (2000) Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J 351(Pt 3):629-637
35. Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, Choi HJ, Yun CO (2007) VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 15:295-302 (Pubitemid 46111879)
36. Zeng H, Sanyal S, Mukhopadhyay D (2001) Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276:32714-32719
37. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898-1903 (Pubitemid 46638989)